Credit Suisse’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-42,577
| Closed | -$4.34M | – | 3192 |
|
|
2023
Q2 | $4.34M | Buy |
42,577
+1,101
| +3% | +$104K | ﹤0.01% | 1432 |
|
|
2023
Q1 | $3.77M | Buy |
41,476
+2,334
| +6% | +$137K | ﹤0.01% | 1499 |
|
|
2022
Q4 | $1.49M | Buy |
39,142
+9,452
| +32% | +$325K | ﹤0.01% | 2057 |
|
|
2022
Q3 | $747K | Buy |
29,690
+158
| +0.5% | +$4.38K | ﹤0.01% | 2536 |
|
|
2022
Q2 | $898K | Buy |
29,532
+1,407
| +5% | +$42K | ﹤0.01% | 2474 |
|
|
2022
Q1 | $921K | Buy |
28,125
+1,165
| +4% | +$34.6K | ﹤0.01% | 2594 |
|
|
2021
Q4 | $711K | Sell |
26,960
-765
| -3% | -$59.2K | ﹤0.01% | 3574 |
|
|
2021
Q3 | $2.79M | Buy |
27,725
+2,026
| +8% | +$237K | ﹤0.01% | 2551 |
|
|
2021
Q2 | $3.64M | Buy |
25,699
+705
| +3% | +$79.6K | ﹤0.01% | 2362 |
|
|
2021
Q1 | $2.49M | Buy |
24,994
+4,315
| +21% | +$503K | ﹤0.01% | 2649 |
|
|
2020
Q4 | $2.56M | Buy |
20,679
+1,056
| +5% | +$139K | ﹤0.01% | 2638 |
|
|
2020
Q3 | $1.91M | Buy |
19,623
+355
| +2% | +$44.4K | ﹤0.01% | 2451 |
|
|
2020
Q2 | $3.01M | Sell |
19,268
-9,741
| -34% | -$1.48M | ﹤0.01% | 2062 |
|
|
2020
Q1 | $4.19M | Sell |
29,009
-13,603
| -32% | -$2.63M | ﹤0.01% | 1652 |
|
|
2019
Q4 | $8.71M | Buy |
42,612
+21,776
| +105% | +$3.97M | 0.01% | 1495 |
|
|
2019
Q3 | $1.67M | Buy |
20,836
+6,233
| +43% | +$529K | ﹤0.01% | 2617 |
|
|
2019
Q2 | $1.38M | Sell |
14,603
-13,922
| -49% | -$1.2M | ﹤0.01% | 2708 |
|
|
2019
Q1 | $2.44M | Buy |
28,525
+5,410
| +23% | +$449K | ﹤0.01% | 2231 |
|
|
2018
Q4 | $1.3M | Buy |
23,115
+1,549
| +7% | +$94.6K | ﹤0.01% | 2579 |
|
|
2018
Q3 | $1.76M | Sell |
21,566
-1,486
| -6% | -$105K | ﹤0.01% | 2445 |
|
|
2018
Q2 | $806K | Buy |
23,052
+4,708
| +26% | +$143K | ﹤0.01% | 3169 |
|
|
2018
Q1 | $376K | Buy |
18,344
+606
| +3% | +$15.6K | ﹤0.01% | 3493 |
|
|
2017
Q4 | $502K | Buy |
17,738
+8,686
| +96% | +$242K | ﹤0.01% | 3433 |
|
|
2017
Q3 | $282K | Buy |
+9,052
| New | +$272K | ﹤0.01% | 3769 |
|
Other funds holding RETA
Credit Suisse's RETA Position: Q3 2023 in Review
Credit Suisse sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 42,577 shares — an estimated $4.34M sold.
Credit Suisse first reported a position in RETA in Q3 2017 and held it in 24 quarters. The position peaked at $8.71M in Q4 2019. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.
- Credit Suisse reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
- Credit Suisse sold 42,577 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $4.34M.
- Credit Suisse first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2017 and held it in 24 quarters.
- Credit Suisse's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $8.71M in Q4 2019.
- 2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.
Based on Credit Suisse's 13F filing for Q3 2023, filed 13 Nov 2023.